1. Home
  2. CNQ vs VRTX Comparison

CNQ vs VRTX Comparison

Compare CNQ & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canadian Natural Resources Limited

CNQ

Canadian Natural Resources Limited

HOLD

Current Price

$49.81

Market Cap

89.8B

Sector

N/A

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$553.25

Market Cap

123.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CNQ
VRTX
Founded
1973
1989
Country
Canada
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
89.8B
123.4B
IPO Year
2001
2006

Fundamental Metrics

Financial Performance
Metric
CNQ
VRTX
Price
$49.81
$553.25
Analyst Decision
Strong Buy
Buy
Analyst Count
2
29
Target Price
$57.00
$539.69
AVG Volume (30 Days)
5.5M
1.2M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
3.68%
N/A
EPS Growth
N/A
836.54
EPS
N/A
8.33
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$5.85
$10.79
Revenue Next Year
N/A
$10.47
P/E Ratio
$18.33
$65.74
Revenue Growth
N/A
46.20
52 Week Low
$29.68
$374.17
52 Week High
$51.48
$555.32

Technical Indicators

Market Signals
Indicator
CNQ
VRTX
Relative Strength Index (RSI) 65.11 67.74
Support Level $44.42 $458.05
Resistance Level $51.16 N/A
Average True Range (ATR) 0.86 13.77
MACD 0.23 3.82
Stochastic Oscillator 80.61 93.74

Price Performance

Historical Comparison
CNQ
VRTX

About CNQ Canadian Natural Resources Limited

Canadian Natural Resources is the largest producer of oil and the second-largest producer of natural gas in Canada. It is principally involved in extracting heavy oils, natural gas, and bitumen through its drilling and mining operations. Bitumen from mining operations is upgraded into synthetic crude oil. Commodities produced are primarily exported to the US via pipeline. The company also has smaller offshore production operations in the North Sea and Africa.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: